CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences
C Vitale, P Strati - Frontiers in oncology, 2020 - frontiersin.org
Chimeric antigen receptor-modified (CAR) T cells targeting CD19 have revolutionized the
treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has …
treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has …
[HTML][HTML] Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies
Chimeric antigen receptor T cell (CAR T) therapy has changed the treatment landscape of
relapsed/refractory lymphoid malignancies. With an expanding pool of post–CAR T cell …
relapsed/refractory lymphoid malignancies. With an expanding pool of post–CAR T cell …
[HTML][HTML] Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis
GK Reynolds, B Sim, T Spelman, A Thomas… - Critical Reviews in …, 2023 - Elsevier
Abstract A registered (PROSPERO-CRD42022346462) systematic review and meta-
analysis was conducted of all-grade infections amongst adult patients receiving CAR-T …
analysis was conducted of all-grade infections amongst adult patients receiving CAR-T …
Recognizing and grading CAR T-cell toxicities: an advanced practitioner perspective
S Sievers, G Watson, S Johncy, S Adkins - Frontiers in Oncology, 2020 - frontiersin.org
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly
improved the outlook for many patients with relapsed and/or refractory B-cell malignancies …
improved the outlook for many patients with relapsed and/or refractory B-cell malignancies …
Chimeric antigen receptor T‐cell therapy toxicities
U Greenbaum, P Kebriaei, SA Srour… - British journal of …, 2021 - Wiley Online Library
Cancer immunotherapy has greatly advanced in recent years, with chimeric antigen receptor
(CAR) T cells emerging as an innovative technology that harnesses the immune system to …
(CAR) T cells emerging as an innovative technology that harnesses the immune system to …
Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus …
R Cui, C Lyu, Q Li, Y Jiang, N Mou… - Hematological …, 2021 - Wiley Online Library
Chimeric antigen receptor‐T (CAR‐T) cell therapy is a promising treatment for CD19+ B‐cell
malignancies. However, elimination of B cells by anti‐CD19 CAR‐T cells may lead to the …
malignancies. However, elimination of B cells by anti‐CD19 CAR‐T cells may lead to the …
Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations
JE Maakaron, M Hu, N El Jurdi - bmj, 2022 - bmj.com
Chimeric antigen receptor T cells have revolutionized the treatment of hematological
malignancies during the past five years, boasting impressive response rates and durable …
malignancies during the past five years, boasting impressive response rates and durable …
CAR-T cell: toxicities issues: mechanisms and clinical management
CAR-T cells are modified T cells expressing a chimeric antigen receptor targeting a specific
antigen. They have revolutionized the treatment of B cell malignancies (aggressive …
antigen. They have revolutionized the treatment of B cell malignancies (aggressive …
Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?
A Di Rocco, M Di Palma, GM D'Elia, G Iaquinta… - Annals of …, 2023 - Springer
Dear Editor, CD19-targeted chimeric antigen receptor-modified T-cell (CAR-T cell)
immunotherapy has shown excellent anti-tumor activity in patients with relapsed/refractory …
immunotherapy has shown excellent anti-tumor activity in patients with relapsed/refractory …
A Phase 1 Dose Escalation Trial of Third Generation Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed and Refractory B-Cell Non Hodgkin Lymphoma
P George - 2020 - openaccess.wgtn.ac.nz
Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy is shifting the treatment
paradigm internationally for selected patients with relapsed and refractory B-cell Non …
paradigm internationally for selected patients with relapsed and refractory B-cell Non …